TARGET THERAPY OF HIGH DIFFERENTIATED CARCINOMA RESISTANT TO RADIOIOD THERAPY (REVIEW OF LITERATURE)
Highly differentiated thyroid cancer refers to the non-aggressive tumors due to the fact, that it can grow slowly and does not metastasize into surrounding tissues and organs. Modern medicine has the ability to cope with this disease, identify it in the early stages and begin timely treatment, which...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2017-11-01
|
| Series: | Опухоли головы и шеи |
| Subjects: | |
| Online Access: | https://ogsh.abvpress.ru/jour/article/view/294 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849401658766786560 |
|---|---|
| author | S. V. Vasilkov A. P. Isaev I. S. Pimenova A. A. Ilyin F. E. Sevryukov |
| author_facet | S. V. Vasilkov A. P. Isaev I. S. Pimenova A. A. Ilyin F. E. Sevryukov |
| author_sort | S. V. Vasilkov |
| collection | DOAJ |
| description | Highly differentiated thyroid cancer refers to the non-aggressive tumors due to the fact, that it can grow slowly and does not metastasize into surrounding tissues and organs. Modern medicine has the ability to cope with this disease, identify it in the early stages and begin timely treatment, which includes surgery and subsequent radioiodine therapy according to the indications. At the same time, the resistance of distant metastases to radioiodine therapy in patients with highly differentiated thyroid cancer significantly worsens the survival prognosis. Results of the use of chemotherapy do not allow recommend it as a therapy of choice. Today the achievements of antitumoral drug treatment are mainly related to the development of targeted therapy, namely, using individual tyrosine kinase inhibitors, in particular Sorafenib, which became the first registered in Russia drug, proved its therapeutic effectiveness in patients with this pathology, whose treatment options are currently extremely limited or absent. |
| format | Article |
| id | doaj-art-d5ef0ed52eee44c0944201bbfcb087df |
| institution | Kabale University |
| issn | 2222-1468 2411-4634 |
| language | Russian |
| publishDate | 2017-11-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Опухоли головы и шеи |
| spelling | doaj-art-d5ef0ed52eee44c0944201bbfcb087df2025-08-20T03:37:43ZrusABV-pressОпухоли головы и шеи2222-14682411-46342017-11-01739610210.17650/2222-1468-2017-7-3-96-102267TARGET THERAPY OF HIGH DIFFERENTIATED CARCINOMA RESISTANT TO RADIOIOD THERAPY (REVIEW OF LITERATURE)S. V. Vasilkov0A. P. Isaev1I. S. Pimenova2A. A. Ilyin3F. E. Sevryukov4A. F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiology Center, Ministry of Health of Russia.A. F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiology Center, Ministry of Health of Russia.A. F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiology Center, Ministry of Health of Russia.A. F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiology Center, Ministry of Health of Russia.A. F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiology Center, Ministry of Health of Russia.Highly differentiated thyroid cancer refers to the non-aggressive tumors due to the fact, that it can grow slowly and does not metastasize into surrounding tissues and organs. Modern medicine has the ability to cope with this disease, identify it in the early stages and begin timely treatment, which includes surgery and subsequent radioiodine therapy according to the indications. At the same time, the resistance of distant metastases to radioiodine therapy in patients with highly differentiated thyroid cancer significantly worsens the survival prognosis. Results of the use of chemotherapy do not allow recommend it as a therapy of choice. Today the achievements of antitumoral drug treatment are mainly related to the development of targeted therapy, namely, using individual tyrosine kinase inhibitors, in particular Sorafenib, which became the first registered in Russia drug, proved its therapeutic effectiveness in patients with this pathology, whose treatment options are currently extremely limited or absent.https://ogsh.abvpress.ru/jour/article/view/294highly differentiated thyroid cancerradioiodresistancetargeted therapy |
| spellingShingle | S. V. Vasilkov A. P. Isaev I. S. Pimenova A. A. Ilyin F. E. Sevryukov TARGET THERAPY OF HIGH DIFFERENTIATED CARCINOMA RESISTANT TO RADIOIOD THERAPY (REVIEW OF LITERATURE) Опухоли головы и шеи highly differentiated thyroid cancer radioiodresistance targeted therapy |
| title | TARGET THERAPY OF HIGH DIFFERENTIATED CARCINOMA RESISTANT TO RADIOIOD THERAPY (REVIEW OF LITERATURE) |
| title_full | TARGET THERAPY OF HIGH DIFFERENTIATED CARCINOMA RESISTANT TO RADIOIOD THERAPY (REVIEW OF LITERATURE) |
| title_fullStr | TARGET THERAPY OF HIGH DIFFERENTIATED CARCINOMA RESISTANT TO RADIOIOD THERAPY (REVIEW OF LITERATURE) |
| title_full_unstemmed | TARGET THERAPY OF HIGH DIFFERENTIATED CARCINOMA RESISTANT TO RADIOIOD THERAPY (REVIEW OF LITERATURE) |
| title_short | TARGET THERAPY OF HIGH DIFFERENTIATED CARCINOMA RESISTANT TO RADIOIOD THERAPY (REVIEW OF LITERATURE) |
| title_sort | target therapy of high differentiated carcinoma resistant to radioiod therapy review of literature |
| topic | highly differentiated thyroid cancer radioiodresistance targeted therapy |
| url | https://ogsh.abvpress.ru/jour/article/view/294 |
| work_keys_str_mv | AT svvasilkov targettherapyofhighdifferentiatedcarcinomaresistanttoradioiodtherapyreviewofliterature AT apisaev targettherapyofhighdifferentiatedcarcinomaresistanttoradioiodtherapyreviewofliterature AT ispimenova targettherapyofhighdifferentiatedcarcinomaresistanttoradioiodtherapyreviewofliterature AT aailyin targettherapyofhighdifferentiatedcarcinomaresistanttoradioiodtherapyreviewofliterature AT fesevryukov targettherapyofhighdifferentiatedcarcinomaresistanttoradioiodtherapyreviewofliterature |